跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VITRAKVI larotrectinib (as sulfate) 20 mg/mL bottle - TGA Drug Approval Details
Approvals
/
TGA
/
VITRAKVI larotrectinib (as sulfate) 20 mg/mL bottle
Approved
STANDARD
VITRAKVI larotrectinib (as sulfate) 20 mg/mL bottle
Bayer Australia Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
20b0a28376b669a2
Company
Bayer Australia Ltd
Type
Standard
Approval Details
Approval Id
20b0a28376b669a2
Product Name
VITRAKVI larotrectinib (as sulfate) 20 mg/mL bottle
Artg Id
388084
Artg Name
VITRAKVI larotrectinib (as sulfate) 20 mg/mL bottle
Sponsor
Bayer Australia Ltd
Company Detail Path
/organization/bayer-australia-ltd
Artg Date
2022-09-20
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
REP
Consumer Medicine Info
https://medical-cdn.nocode.com/drug_tga/74e3eb8086e1935a5eeaa55dc9f05654.pdf
Product Information
https://medical-cdn.nocode.com/drug_tga/91c2ee80844939c64859343d93ff25a3.pdf
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
20b0a28376b669a2
Type
Standard
Back to TGA Approvals